India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The acquisition is based on an enterprise value of Rs. 1,660 crore
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Establishing Asymchem’s first manufacturing footprint in Europe
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated
